The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Cell-Type-Specific Responses to Interleukin-1 Control Microbial Invasion and Tumor-Elicited Inflammation in Colorectal Cancer
Open accessAbstract
Summary Chronic inflammation drives the progression of colorectal cancer (CRC). Increased expression of interleukin (IL)‐17A is associated with poor prognosis, and IL‐17A blockade curbs tumor progression in preclinical models of CRC. Here we examined the impact of IL‐1 signaling, a key regulator of the IL‐17 pathway, in different cell types within the CRC microenvironment. Genetic deletion of the IL‐1 receptor (IL‐1R1) in epithelial cells alleviated tumorigenesis in the APC model of CRC, demonstrating a cell‐autonomous role for IL‐1 signaling in early tumor seed outgrowth. T cell specific ablation of IL‐1R1 decreased tumor‐elicited inflammation dependent on IL‐17 and IL‐22, thereby reducing CRC progression. The pro‐tumorigenic roles of IL‐1 were counteracted by its effects on myeloid cells, particularly neutrophils, where IL‐1R1 ablation resulted in bacterial invasion into tumors, heightened inflammation and aggressive CRC progression. Thus, IL‐1 signaling elicits cell‐type‐specific responses, which, in aggregate, set the inflammatory tone of the tumor microenvironment and determine the propensity for disease progression. Graphical Abstract Figure. No Caption available. HighlightsIL‐1R regulates inflammation, but its blanket inactivation does not reduce CRCDeletion of IL‐1R in epithelium delays CRC development independent of inflammationT‐cell‐specific IL‐1R deletion reduces TEI cytokine expression and CRC progressionMyeloid IL‐1R deletion promotes tumor‐specific dysbiosis, inflammation and CRC growth &NA; Dmitrieva‐Posocco et al. use conditional gene deletion approaches in a model of colorectal cancer and find that IL‐1 has distinct effects on different cell types in the tumor microenvironment. The tumor‐promoting effects of IL‐1 are both inflammation dependent and independent, whereas its tumor‐suppressive effects rely on neutrophil‐mediated control of bacterial invasion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399 · cited 1×
“Although chronic inflammation is a well-established driver in many cancers (Mantovani et al., 2008), inflammation also appears to play a deleterious role in cancers without overt underlying inflammatory etiologies.”
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898 · cited 1×
“Moreover IL-1 can play a role of a ‘‘danger signal,’’ when released from necrotizing cells (Ghiringhelli et al., 2009).”
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Coffelt, S. B., Kersten, K., Doornebal, C. W., Weiden, J., Vrijland, K., Hau, C.-S., Verstegen, N. J. M., Ciampricotti, M., Hawinkels, L. J. A. C., Jonkers, J., et al. (2015) · Nature · doi:10.1038/nature14282 · Cited by 1,703 · cited 1×
“Neutrophils and IL-1 signaling are critical for breast cancer metastasis but not primary tumor growth (Coffelt et al., 2015), and environmental and dietary factors can drive inflammasome/IL-1 dependent breast cancer (Kolb et al., 2016).”
Adenoma–linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
Grivennikov, S. I., Wang, K., Mucida, D., Stewart, C. A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G.-Y., Österreicher, C. H., Hung, K. E., et al. (2012) · Nature · doi:10.1038/nature11465 · Cited by 1,327 · cited 8×
“, 2011) and promotesCRC in various animal models (Blatner et al., 2012; Grivennikov et al., 2012; Huber et al., 2012; Kirchberger et al., 2013).”
InfluentialSelf-citationRothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984
Bruttger, J., Karram, K., Wörtge, S., Regen, T., Marini, F., Hoppmann, N., Klein, M., Blank, T., Yona, S., Wolf, Y., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.012 · Cited by 634 · cited 3×
“129P2(Cg)-Rorctm2Litt/J Stock 007572 Mouse: Il1r1 Ari Waisman (University of Mainz) (Bruttger et al., 2015) MGI: 5792908 Mouse: Ly6GCre-Il1r1 Ari Waisman and Matthias Gunzer (University Mainz and University Duisburg-Essen) (Hasenberg et al.”
InfluentialSelf-citationInnate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model
Kirchberger, S., Royston, D. J., Boulard, O., Thornton, E., Franchini, F., Szabady, R. L., Harrison, O., & Powrie, F. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20122308 · Cited by 529
Sakurai, T., He, G., Matsuzawa, A., Yu, G.-Y., Maeda, S., Hardiman, G., & Karin, M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.016 · Cited by 487 · cited 1×
“Inactivation of IL-1a and MyD88 reduces liver carcinogenesis in DENmodel (Sakurai et al., 2008).”
Cited by
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
“For instance, cytokine receptor signaling in mutated cells may converge at the induction of pro-survival pathways particularly mediated by NF-κB, STAT3 and other types of signaling (Dmitrieva-Posocco et al., 2019; Greten and Karin, 2005; Grivennikov et al., 2009), thereby increasing the survival probability of surviva…”
BackgroundSelf-citationNeutrophil diversity and plasticity in tumour progression and therapy
Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R., & Mantovani, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0281-y · Cited by 1,285
NLRP3 inflammasome in cancer and metabolic diseases
Sharma, B. R., & Kanneganti, T.-D. (2021) · Nature Immunology · doi:10.1038/s41590-021-00886-5 · Cited by 1,097
Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity
Mantovani, A., Dinarello, C. A., Molgora, M., & Garlanda, C. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.012 · Cited by 1,046
Interleukins in cancer: from biology to therapy
Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00363-z · Cited by 781
The inflammatory pathogenesis of colorectal cancer
Schmitt, M., & Greten, F. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00534-x · Cited by 775
Neutrophils in cancer: heterogeneous and multifaceted
Hedrick, C. C., & Malanchi, I. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00571-6 · Cited by 768
Targeting immune cell circuits and trafficking in inflammatory bowel disease
Neurath, M. F. (2019) · Nature Immunology · doi:10.1038/s41590-019-0415-0 · Cited by 701
Diverging inflammasome signals in tumorigenesis and potential targeting
Karki, R., & Kanneganti, T.-D. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0123-y · Cited by 641
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Embracing cancer complexity: Hallmarks of systemic disease
Swanton, C., Bernard, E., Abbosh, C., André, F., Auwerx, J., Balmain, A., Bar-Sagi, D., Bernards, R., Bullman, S., DeGregori, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.009 · Cited by 540
Meta-hallmarks of aging and cancer
López-Otín, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.001 · Cited by 529
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
Nakamura, K., & Smyth, M. J. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0306-1 · Cited by 516
The role of IL-22 in intestinal health and disease
Keir, M. E., Yi, T., Lu, T. T., & Ghilardi, N. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20192195 · Cited by 464
Host–microbiota maladaptation in colorectal cancer
Janney, A., Powrie, F., & Mann, E. H. (2020) · Nature · doi:10.1038/s41586-020-2729-3 · Cited by 445
IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer
Caronni, N., La Terza, F., Vittoria, F. M., Barbiera, G., Mezzanzanica, L., Cuzzola, V., Barresi, S., Pellegatta, M., Canevazzi, P., Dunsmore, G., et al. (2023) · Nature · doi:10.1038/s41586-023-06685-2 · Cited by 393
Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?
Hou, J., Karin, M., & Sun, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00459-9 · Cited by 366
Rébé, C., & Ghiringhelli, F. (2020) · Cancers · doi:10.3390/cancers12071791 · Cited by 337
Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity
Hou, J., Hsu, J.-M., & Hung, M.-C. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.09.003 · Cited by 301
Immunotherapy, Inflammation and Colorectal Cancer
Lichtenstern, C. R., Ngu, R. K., Shalapour, S., & Karin, M. (2020) · Cells · doi:10.3390/cells9030618 · Cited by 294
IL-1 Family Members in Cancer; Two Sides to Every Story
Baker, K. J., Houston, A., & Brint, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01197 · Cited by 284
Bouhamida, E., Morciano, G., Perrone, M., Kahsay, A. E., Della Sala, M., Wieckowski, M. R., Fiorica, F., Pinton, P., Giorgi, C., & Patergnani, S. (2022) · Biology · doi:10.3390/biology11020300 · Cited by 87
IL-22 Signaling in the Tumor Microenvironment
Jiang, R., & Sun, B. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-55617-4_5 · Cited by 35
Metadata
- Authors
- Dmitrieva-Posocco, O., Dzutsev, A., Posocco, D. F., Hou, V., Yuan, W., Thovarai, V., Mufazalov, I. A., Gunzer, M., Shilovskiy, I. P., Khaitov, M. R., Trinchieri, G., Waisman, A., & Grivennikov, S. I.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 50
- Issue
- 1
- Pages
- 166-180.e7
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W2910570709
- Cited by
- 188
- References
- 11
- FWCI
- 7.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.